How to buy Kiromic BioPharma stock | $8.12

Kiromic BioPharma, Inc is a biotechnology business based in the US. Kiromic BioPharma shares (KRBP) are listed on the NASDAQ and all prices are listed in US Dollars. Kiromic BioPharma employs 19 staff and has a market cap (total outstanding shares value) of 0.00.

Kiromic BioPharma stock price (NASDAQ: KRBP)

Use our graph to track the performance of KRBP stocks over time.

Kiromic BioPharma shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$8.12
52-week range	$2.87 - $12.11
50-day moving average	$6.80
200-day moving average	$8.51
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Kiromic BioPharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Kiromic BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Kiromic BioPharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kiromic BioPharma price performance over time

Historical closes compared with the close of $8.12 from 2021-05-28

1 week (2021-07-19)	N/A
1 month (2021-06-30)	68.81%
3 months (2021-04-30)	-3.91%
6 months (2021-01-26)	N/A

1 year (2020-07-26)	N/A
2 years (2019-07-26)	N/A
3 years (2018-07-26)	N/A
5 years (2016-07-26)	N/A

Kiromic BioPharma financials

Gross profit TTM	$0
Return on assets TTM	-182.1%
Return on equity TTM	-352.34%
Profit margin	0%
Book value	$1.15
Market capitalisation	$49.2 million

TTM: trailing 12 months

Shorting Kiromic BioPharma shares

There are currently 178,676 Kiromic BioPharma shares held short by investors – that's known as Kiromic BioPharma's "short interest". This figure is 392.5% up from 36,277 last month.

There are a few different ways that this level of interest in shorting Kiromic BioPharma shares can be evaluated.

Kiromic BioPharma's "short interest ratio" (SIR)

Kiromic BioPharma's "short interest ratio" (SIR) is the quantity of Kiromic BioPharma shares currently shorted divided by the average quantity of Kiromic BioPharma shares traded daily (recently around 232046.75324675). Kiromic BioPharma's SIR currently stands at 0.77. In other words for every 100,000 Kiromic BioPharma shares traded daily on the market, roughly 770 shares are currently held short.

To gain some more context, you can compare Kiromic BioPharma's short interest ratio against those of similar companies.

• BeiGene (BGNE.US): 15.65
• BioNTech (BNTX.US): 0.9
• Bio-Techne Corporation (TECH.US): 1.93
• XBiotech (XBIT.US): 10.42

However Kiromic BioPharma's short interest can also be evaluated against the total number of Kiromic BioPharma shares, or, against the total number of tradable Kiromic BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kiromic BioPharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Kiromic BioPharma shares in existence, roughly 20 shares are currently held short) or 0.0372% of the tradable shares (for every 100,000 tradable Kiromic BioPharma shares, roughly 37 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kiromic BioPharma.

Find out more about how you can short Kiromic BioPharma stock.

Kiromic BioPharma share dividends

We're not expecting Kiromic BioPharma to pay a dividend over the next 12 months.

You may also wish to consider:

• Bio-Techne Corporation (TECH.US) (0.28% forward annual dividend yield)

Kiromic BioPharma overview

Kiromic BioPharma, Inc. , a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc. ; and Longwood University, as well as research and development collaboration agreements with Molipharma, S. R. L.

Frequently asked questions

What percentage of Kiromic BioPharma is owned by insiders or institutions?
Currently 32.038% of Kiromic BioPharma shares are held by insiders and 9.211% by institutions. How many people work for Kiromic BioPharma?
Latest data suggests 19 work at Kiromic BioPharma. When does the fiscal year end for Kiromic BioPharma?
Kiromic BioPharma's fiscal year ends in December. Where is Kiromic BioPharma based?
Kiromic BioPharma's address is: 7707 Fannin, Houston, TX, United States, 77054 What is Kiromic BioPharma's ISIN number?
Kiromic BioPharma's international securities identification number is: US4976341051